

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for May 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Amlodipine	Norvasc	AMLODIPINE BESYLATE	2.5 mg	tablet	02357186
Marcan Pharmaceuticals Inc.	Mar-Fluoxetine	Prozac	FLUOXETINE HCl	10 mg	tablet	02392909
Jamp Pharma Corporation	Jamp Zopiclone	Imovane	ZOPICLONE	7.5mg	tablet	02549301